Acumen Pharmaceuticals has concluded enrolment for its multi-centre, double-blind Phase II ALTITUDE-AD trial of humanised ...

CDR-Life develops highly targeted T cell engagers ... demonstrates the potential of our antibody-derived molecules. Backed by leading cross-Atlantic investors, our team is committed to bringing ...

Portfolio Expansion: CDR111 CDR111, CDR-Life's newest clinical candidate ... AACR Poster Presentation Details Title: A novel T cell engager antibody for the treatment of HLA-A*01/KK-LC-1-positive ...

ZÜRICH, March 25, 2025--(BUSINESS WIRE)--CDR-Life today announced the expansion of its product portfolio with the nomination of CDR111 as a new clinical candidate for autoimmune diseases along ...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

After hours: March 26 at 7:49:06 p.m. EDT Loading Chart for IPA ...

Sabirnetug is the first humanized monoclonal antibody to demonstrate in AD patients selective target engagement of ... Secondary endpoints include the Clinical Dementia Rating - Sum of Boxes scale ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with ...